Live News Categoriesequity

AptaBio Therapeutics Inc. (293780.KQ) News

Follow AptaBio Therapeutics Inc. (293780.KQ) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol 293780.KQ Asset equity Sector Markets 90 days 1 Last 6,650 Updated Oct 14, 2026, 09:05 AM UTC Open live news feed

H AptaBio receives Phase 2 topline data for APX — 115 in contrast — induced acute kidney injury trial AptaBio received topline Phase 2 data for Isuzinaxib (APX-115) in contrast-induced acute kidney injury on Oct. 14, 2026. The study met its primary safety objective, with no clinically meaningful safety signals versus pla NEWS | Oct 14, 2026, 09:05 AM UTC